Amylyx Pharmaceuticals annual shares outstanding
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Shares Outstanding History (AMLX)
Amylyx Pharmaceuticals reported 109.9M shares outstanding at the end of fiscal 2025.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 109.9M | 41.3M | +60.11% |
| 2024 | 2024-12-31 | 68.6M | 922,306 | +1.36% |
| 2023 | 2023-12-31 | 67.7M | 1.2M | +1.80% |
| 2022 | 2022-12-31 | 66.5M | 59.5M | +847.40% |
| 2021 | 2021-12-31 | 7.0M | — | — |
Amylyx Pharmaceuticals quarterly shares outstanding
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 111.4M | 22.2M | +24.91% |
| Q1 2026 | 2026-03-31 | 111.0M | 21.9M | +24.64% |
| Q4 2025 | 2025-12-31 | 109.9M | 41.3M | +60.11% |
| Q3 2025 | 2025-09-30 | 109.8M | 41.2M | +60.14% |
| Q2 2025 | 2025-06-30 | 89.2M | 21.1M | +30.96% |
| Q1 2025 | 2025-03-31 | 89.1M | 21.1M | +31.05% |
| Q4 2024 | 2024-12-31 | 68.6M | 922,306 | +1.36% |
| Q3 2024 | 2024-09-30 | 68.5M | 1.0M | +1.54% |
| Q2 2024 | 2024-06-30 | 68.1M | 724,640 | +1.08% |
| Q1 2024 | 2024-03-31 | 68.0M | 879,984 | +1.31% |
| Q4 2023 | 2023-12-31 | 67.7M | 1.2M | +1.80% |
| Q3 2023 | 2023-09-30 | 67.5M | 9.0M | +15.33% |
| Q2 2023 | 2023-06-30 | 67.4M | 8.8M | +15.07% |
| Q1 2023 | 2023-03-31 | 67.1M | 9.2M | +15.95% |
| Q4 2022 | 2022-12-31 | 66.5M | 59.5M | +847.40% |
| Q3 2022 | 2022-09-30 | 58.5M | — | — |
| Q2 2022 | 2022-06-30 | 58.5M | — | — |
| Q1 2022 | 2022-03-31 | 57.9M | — | — |
| Q4 2021 | 2021-12-31 | 7.0M | — | — |
Amylyx Pharmaceuticals shares outstanding trends
Across the available reported history, Amylyx Pharmaceuticals's shares outstanding moved from 68.6M to 109.9M, a change of 41.3M. The latest reported quarter, Q2 2026, shows 111.4M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amylyx Pharmaceuticals filings at SEC.gov ↗